このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase I of FXS0260 in Advanced Solid Tumor

This Study is a Phase I, Single-arm, Open-label, Dose-escalation and Dose-expansion Clinical Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of FXS0260 in Participants With Advanced Solid Tumors.

This study is a Phase I, single-arm, open-label, dose-escalation and dose-expansion clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of FXS0260 in participants with advanced solid tumors.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

The study consists of two parts: Phase Ia dose escalation and Phase Ib dose expansion.

Phase Ia is an open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of FXS0260 in participants with advanced solid tumors. Approximately 20 participants are expected to be enrolled.

Dose escalation will be conducted using an accelerated titration design combined with the Bayesian Optimal Interval (BOIN) design. The prespecified dose levels are 5 mg BID, 20 mg BID, 60 mg BID, 120 mg BID, and 180 mg BID.

The accelerated titration design will be applied to the 5 mg BID and 20 mg BID dose cohorts, while the BOIN design will be implemented starting from the 60 mg BID dose cohort.Only one participant will initially be enrolled in each of the 5 mg BID and 20 mg BID dose cohorts. If a dose-limiting toxicity (DLT) or a Grade ≥2 study drug-related adverse event (AE) occurs during the DLT observation period, the current dose cohort will transition to the BOIN design, with enrollment expanded to a total of 3 participants.

Participants will receive a single oral dose of FXS0260 under fasting conditions during the single-dose administration period. The DLT observation period will be 24 days following the first dose (including the single-dose administration period and Cycle 1). Participants will subsequently enter Cycle 2 and subsequent cycles for multiple-dose treatment.Study treatment will continue until disease progression, death, unacceptable toxicity, withdrawal of informed consent, or other reasons requiring discontinuation of study treatment, whichever occurs first.

Phase Ib is an open-label, dose-expansion study that will enroll eligible participants with advanced solid tumors. The sample size will be determined based on the results of the Phase Ia dose-escalation study.This phase aims to further evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of FXS0260 at the recommended dose level(s) for expansion (1-2 dose cohorts).

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200000
        • Fudan University Shanghai Cancer Center
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Male or female participants aged ≥18 years;

  2. Fully understand the requirements of this study and voluntarily sign the written informed consent form;

  3. Participants with histologically/cytologically diagnosed advanced solid tumors who have received standard treatment before participating in this study and for whom standard treatment has failed or no standard treatment is available; priority will be given to participants with advanced endometrial cancer, advanced ovarian cancer, advanced colorectal cancer, advanced gastric cancer, and advanced breast cancer;

  4. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 (lesions previously treated with radiotherapy cannot be considered target lesions unless obvious progression has occurred);

  5. Eastern Cooperative Oncology Group performance status score of 0-1;

  6. Life expectancy ≥12 weeks;

  7. Adequate organ and bone marrow function:

    Hematology (no red blood cell or platelet transfusion or growth factor infusion within 7 days before the first administration of FXS0260):

    • Hemoglobin ≥95 g/L;
    • ANC ≥1.5 × 10⁹/L (≥1500 cells/mm³);
    • Platelet count ≥100 × 10⁹/L (≥100,000 cells/mm³);

    Coagulation:

    • Prothrombin time and APTT ≤1.5 × ULN;
    • INR ≤1.5 × ULN.

    Liver:

    • Total bilirubin ≤1.5 × ULN (if the participant is diagnosed with Gilbert's syndrome, total bilirubin ≤3 × ULN and direct bilirubin ≤1.5 × ULN are allowed);
    • ALT/AST ≤3 × ULN (≤5 × ULN in the presence of liver metastases).

    Kidney:

    • Creatinine clearance ≥60 mL/min. Creatinine clearance will be calculated using the Cockcroft-Gault formula.
  8. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days before the first administration of the study drug; eligible participants of reproductive potential (male and female) must agree to use reliable contraceptive methods (hormonal or barrier methods or abstinence, etc.) together with their partners during the study and for at least 6 months after the last dose.

Exclusion Criteria:

  1. Participants who are still within the washout period of previous antitumor treatment drugs before the first administration of FXS0260 (4 weeks or 5 half-lives after the last dose, whichever is shorter);

  2. Participants who have previously received PKMYT1 inhibitors;

  3. Participants who have participated in a clinical study within 4 weeks before the first administration of FXS0260;

  4. Participants with a history of allergy to any known component or analogue of FXS0260;

  5. Participants who require strong CYP3A inhibitors and/or inducers and P-gp inhibitors and/or inducers within 14 days (or 5 half-lives, whichever is longer) before the first administration and during the study;

  6. Participants with active infections requiring systemic anti-infective treatment within 1 week before the first administration;

  7. Participants who have received systemic glucocorticoids or other immunosuppressants, such as cyclophosphamide, azathioprine, methotrexate, and anti-tumor necrosis factor α agents, within 14 days before the first administration;

  8. Participants with other malignancies within 3 years before the first administration (except adequately treated basal cell/squamous cell carcinoma of the skin and carcinoma in situ of the cervix/breast);

  9. Participants who have not recovered from adverse events caused by previous antitumor treatment (recovered to Grade 1 or baseline level), except for alopecia, pigmentation of any grade, peripheral sensory neuropathy of Grade ≤2, and items already explicitly specified in the inclusion criteria, as well as other abnormalities that are clinically insignificant or considered to pose no risk by the investigator;

  10. Participants with a significant risk of thrombosis, such as deep vein thrombosis or pulmonary embolism within 3 months before screening, excluding venous thrombosis related to indwelling catheters or other procedures, superficial venous thrombosis, or thrombosis effectively treated with conventional anticoagulant therapy;

  11. Participants with refractory nausea, vomiting, chronic gastrointestinal diseases including but not limited to active diverticulitis and symptomatic peptic ulcers, inability to swallow oral medications, or conditions such as previous extensive small bowel resection that, in the investigator's judgment, seriously affect gastrointestinal absorption;

  12. Participants with a history of or current retinal vein stenosis or occlusion (RVO), retinal pigment epithelial detachment (RPED), central retinal vein occlusion, glaucoma, or other ocular diseases that affect the assessment of ocular toxicity after administration of the investigational product;

  13. Participants who have undergone major surgery within 4 weeks before the first administration or have not recovered from surgical complications;

  14. Participants who have received radiotherapy within 14 days before the first administration;

  15. Participants with symptomatic or unstable brain metastases. Participants with previously treated brain metastases may participate in the study, provided that the following conditions are met: the metastatic lesions are stable (no evidence of progression on imaging examinations within 4 weeks before the first administration of study treatment, and any neurological symptoms are controlled and stable), there is no evidence of new or enlarging brain metastases, the investigator assesses the clinical condition as stable, and steroids have been discontinued for at least 14 days before the first administration of study treatment;

  16. Participants with any of the following cardiovascular diseases:

    • Symptomatic heart failure (New York Heart Association [NYHA] functional classification ≥ Class II);
    • Left ventricular ejection fraction <50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan;
    • Poorly controlled hypertension repeatedly observed despite standard of care (SOC) treatment (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg);
    • Prolonged QT/QTc interval on electrocardiogram during screening (QTcF >470 ms);
    • Acute coronary syndrome/acute myocardial infarction, unstable angina, percutaneous coronary intervention or coronary artery bypass grafting within 6 months before screening;
    • Cardiomyopathy of any etiology or clinically significant valvular heart disease;
    • Transient ischemic attack or stroke within 6 months before screening that, in the investigator's judgment, may affect this study;
    • Severe arrhythmias requiring clinical intervention;
    • Any other cardiovascular disease that, in the investigator's opinion, makes the participant unsuitable for participation in the study.
  17. Participants with uncontrolled pleural effusion, pericardial effusion, or ascites, or pleural effusion, pericardial effusion, or ascites requiring repeated drainage and medical intervention;

  18. Participants with any of the following viral infections at screening:

    • Active hepatitis B: HBV-DNA >500 IU/mL or 2000 copies/mL;
    • Active hepatitis C: positive HCV antibody and positive HCV-RNA;
    • Human immunodeficiency virus (HIV) infection: positive antibody test;
    • Active syphilis: positive Treponema pallidum antibody (such as TPHA or FTA-ABS) and positive titer test (such as RPR or VDRL).
  19. Participants with a history of interstitial lung disease, drug-induced interstitial lung disease or radiation pneumonitis requiring steroid treatment, or clinically active interstitial lung disease;

  20. Participants with known drug abuse or psychiatric disorders that would interfere with compliance with study requirements;

  21. Participants who are pregnant or breastfeeding or intend to become pregnant during the study;

  22. Participants who, in the investigator's opinion, have other factors that may affect the study results or interfere with their participation throughout the study, including previous or existing physical conditions, treatments, or laboratory abnormalities, unwillingness to comply with the study procedures, restrictions, and requirements, or other circumstances that make them unsuitable for enrollment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:FXS0260

Participants will receive FXS0260, an oral small-molecule PKMYT1 inhibitor, at prespecified dose levels of 5, 20, 60, 120, or 180 mg twice daily (BID) during the dose-escalation phase (Phase Ia). Participants will receive a single oral dose during the single-dose administration period, followed by repeated dosing in subsequent treatment cycles.

During the dose-expansion phase (Phase Ib), participants will receive FXS0260 at one or two recommended dose levels selected based on the results of Phase Ia.

Treatment will continue until disease progression, unacceptable toxicity, death, withdrawal of informed consent, or other protocol-defined reasons for treatment discontinuation, whichever occurs first.

FXS0260 is an orally administered, selective small-molecule inhibitor of PKMYT1

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of DLTs
時間枠:From the first dose through Day 24 (Phase Ia only)

DLTs will be assessed during the DLT observation period in Phase Ia. DLT-evaluable participants are defined as those who experience a DLT during the DLT observation period or receive at least 70% of the planned doses and complete the safety assessments.

From the first dose through Day 24 (Phase Ia only)
Determination of MTD or MAD
時間枠:Up to 12 Months

The MTD will be inferre based on DLT data and all safety data observed at all dose levels. The MTD is defined as the highest dose level at which no more than 30% of participants experience a DLT during the DLT observation period in the dose-escalation phase.If the MTD is not reached, the highest safe dose level will be defined as the MAD.

Up to 12 Months
Incidence, Severity, and Relationship to Study Drug of Adverse Events (AEs)
時間枠:From the first dose of FXS0260 through 28 days after the last dose.

The incidence, severity, and relationship to FXS0260 of adverse events will be assessed. The severity of adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0.

From the first dose of FXS0260 through 28 days after the last dose.
Determination of RP2D
時間枠:Through completion of the dose-escalation and dose-expansion assessments

The RP2D of FXS0260 will be determined based on an integrated assessment of safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy data.

Through completion of the dose-escalation and dose-expansion assessments

二次結果の測定

結果測定
メジャーの説明
時間枠
Peak Plasma Concentration (Cmax) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
The area under the plasma concentration-time curve from time 0 to the last measurable ocncentration (AUC0-t)of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Time to reach maximum plasma concentration (Tmax) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Elimination Half-life (T1/2) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Apparent Clearance (CL/F) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Apparent volume of distribution (Vz/F) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Average concentration at steady state(Cavg,ss) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Minimum observed concentration at steady state(Cmin,ss) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Maximum observed concentration at steady state(Cmax,ss)of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Elimination rate constant (λz) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Apparent volume of distribution at steady state(Vss/F) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Area under the plasma concentration time curve from time 0 to infinity(AUC0-∞)of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Area under the plasma concentration-time curve over the dosing interval at steady state (AUCtau,ss) of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Accumulation ratio(AR) based on Cmax of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Accumulation ratio(AR) based on AUCtau, ss of FXS0260
時間枠:From prodose on Day1 to 7 days after last dose of FXS0260

Pharmacokinetic parameter

From prodose on Day1 to 7 days after last dose of FXS0260
Objective response rate, ORR
時間枠:From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.
Progression Free Survival
時間枠:From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.
Duration of Response (DoR)
時間枠:From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.
Disease Control Rate (DCR)
時間枠:From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

Antitumor activity by evaluation of tumor response assessments based on RECIST 1.1

From first dose of study drug until disease progression as defined by RECIST v1.1, initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.
Overall Suivaval (OS)
時間枠:From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

Antitumor activity by evaluation of tumor response assessments based on RECIST 1.2

From first dose of study drug until disease progression as defined by RECIST v1.1 , initiation of new anticancer therapy, death, withdrawal of informed consent, loss to follow-up, or the end of the study, whichever occurs first, assessed up to 24 months.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月15日

一次修了 (推定)

2028年12月15日

研究の完了 (推定)

2029年12月15日

試験登録日

最初に提出

2026年10月25日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • FXS0260-I101

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。